Pancreatic Cancer | Specialty

MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDAC

June 27th 2024

MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.

Mitazalimab Plus mFOLFIRINOX Yields 18-Month OS Benefit in Previously Untreated Metastatic Pancreatic Cancer

June 26th 2024

Frontline mitazalimab plus mFOLFIRINOX generated an OS benefit and prolonged DOR in patients with metastatic pancreatic ductal adenocarcinoma.

Dr Garcia-Carbonero on the Phase 2b VIRAGE Trial in Metastatic PDAC

June 24th 2024

Rocio Garcia-Carbonero, MD, discusses the rationale for the phase 2b VIRAGE trial in patients with metastatic pancreatic cancer.

Addition of XB2001 to Chemo Improves Safety in Advanced Pancreatic Cancer

June 20th 2024

XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.

Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.

Standard Treatment Regimens for NRG1+ Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses current standard therapeutics for patients with NRG1 fusion–positive pancreatic cancer.

Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer.

Prognosis, Rarity of NRG1+ Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses prognosis and rarity of patients with NRG1 fusion–positive pancreatic cancer.

IBI343 Receives FDA Fast Track Designation for Advanced/Metastatic PDAC

June 13th 2024

The FDA granted fast track designation to IBI343 monotherapy for relapsed/refractory advanced unresectable or metastatic pancreatic ductal adenocarcinoma.

Dr Huffman on the Investigation of Azenosertib Plus Gemcitabine in Advanced Pancreatic Cancer

June 11th 2024

Brandon Huffman, MD, discusses an ongoing phase 2 trial evaluating azenosertib plus gemcitabine in advanced pancreatic cancer.

Dr Kamath on the Tumor Microbiome of Early- and Average-Onset PDAC

June 10th 2024

Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.

Exploring the Nuances of Postoperative Considerations in Pancreatic Cancer

June 5th 2024

Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.

Pitavastatin Offers Therapeutic Potential in Cancers Arising From Chronic Inflammation

May 30th 2024

Pitavastatin, an FDA-approved statin, may inhibit pathways that contribute to IL-33 production, which has been shown to contribute to cancer development.

Dr Lim on Multidisciplinary Approaches to Pancreatic Cancer Management

May 23rd 2024

Kian-Huat Lim, MD, PhD, discusses the importance of multidisciplinary collaboration when diagnosing and treating patients with pancreatic cancer.

FDA Grants Fast Track Designation to VCN-01 in Metastatic Pancreatic Cancer

May 23rd 2024

VCN-01 plus gemcitabine and nab-paclitaxel has received fast track designation from the FDA in metastatic pancreatic adenocarcinoma.

FDA Grants Orphan Drug Designation to Azeliragon for Pancreatic Cancer

May 21st 2024

The FDA has granted orphan drug designation to azeliragon as a potential therapeutic option for patients with pancreatic cancer.

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

May 21st 2024

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Capecitabine or XELOX Does Not Significantly Improve Efficacy vs PF in Inoperable ESCC

May 15th 2024

Capecitabine or XELOX failed to improve OS at 2 years vs fluorouracil/cisplatin as DCRT in inoperable locally advanced esophageal squamous cell carcinoma.

Multidisciplinary Collaboration Plays Key Role in Pancreatic Cancer

May 2nd 2024

Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.

Patient Factors, Toxicities Key to Selecting NALIRIFOX or Other Chemo Options in Advanced Pancreatic Cancer

April 30th 2024

Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.